Quarterly report pursuant to Section 13 or 15(d)

Restructuring

v3.24.1.u1
Restructuring
 3 Months Ended
Mar. 31, 2024
Restructuring and Related Activities [Abstract]  
Restructuring Restructuring
The Company incurs costs associated with restructuring initiatives intended to improve operating performance, profitability, and working capital levels. Actions associated with these initiatives may include improving productivity, workforce reductions, and the consolidation of facilities.
As of March 31, 2024, the Company does not expect a significant impact of additional charges from restructuring actions in the next 12 months.
The Company’s restructuring expenses are comprised of the following (in millions):
Three Months Ended March 31, 2024
Cost of revenue Selling, general
 and administrative		 Total
Severance and employee costs $ —  $ —  $ — 
Other(1)
—  —  — 
Total $ —  $ —  $ — 
Three Months Ended March 31, 2023
Cost of revenue Selling, general
 and administrative		 Total
Severance and employee costs $ —  $ 1.2  $ 1.2 
Other(1)
—  0.2  0.2 
Total $ —  $ 1.4  $ 1.4 
(1) Includes facilities, inventory write-downs, outside services, legal matters, and IT costs.
The following table summarizes restructuring expenses for each reportable segment (in millions):
Three Months Ended
March 31,
2024 2023
Restructuring expenses:
Medical $ —  $ 0.3 
Technologies —  0.1 
Corporate and other —  1.0 
Total $ —  $ 1.4 
No amounts were accrued for restructuring in Accrued expenses and other current liabilities in the accompanying unaudited Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023, respectively.